Meridian Bioscience

78 articles about Meridian Bioscience

• Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

  1/6/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021. Jack Kenny will also be participating in a panel discussion hosted by former FDA Commissioner Scott Gottlieb, M.D. on Tuesday, J

• Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2

  12/16/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

• Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

  12/8/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene ® platform. The SARS-CoV-2 test is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the

• Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

  12/3/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed for air-drying, a cost-effective and easier alternative to lyophilization. With this new product addition, Meridian has th

• Meridian Bioscience Participates in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020. To register for access to the pre-recorded fireside chat, go to the Events & Presentations section of the Company’s Investor Relations w

• Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum

  11/16/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020

• Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance

  11/13/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019): Consolidated Net Revenue of $64.2 million, up 26% year-over-year Life Science segment delivers revenue of $34.4 million, up 97% year-over-year Diagnostics segment revenues decreased 11% year-over-year to $29.8 million, a stronger

• Meridian Bioscience to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on November 13, 2020

  10/20/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2020 financial results Friday, November 13, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in t

• Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics

  10/7/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct RNA and DNA detection from liquid biopsy samples such as whole blood.

• Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference

  8/31/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET.

• Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance

  8/7/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020. Third Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $84.8 million, up 75% year-over-year Life Science segment delivers record revenue of $63.2 million, up 312% year-over-year, as a result of strong demand for COVID-19 related products Broadened the Life Science portfolio of COVID-19 related products to i

• Meridian Bioscience Announces New Board Member - Anthony Bihl

  7/28/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. “We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” said David Phillips, Chairman of Meridian Bioscience.  “We were looking to add diagnostics expertise to the board and Tony additionally brings the breadth of leading both large and small public organiza

• Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020

  7/16/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.  To participate in the live call by t

• Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays

  7/13/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.

• Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

  5/20/2020

  Meridian Bioscience, Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.  Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of the Diagnostics division to Mr. Serafini-Lamanna, who becomes an officer of the company.

• Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products

  5/8/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020. Second Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $57.3 million, up 14% year-over-year Life Science segment responded early and swiftly to the COVID-19 pandemic contributing to a record $22.4 million in revenues, up 33% year-over-year Diagnostics segment delivered over $34.9 million in revenue, the fifth con

• Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

  5/6/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use. 

• Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

  4/30/2020

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.